AI Tools Directory
Discover and compare the best AI tools for your business
Discover and compare the best AI tools for your business
Cleerly determines your risk of heart attack by performing a non-invasive whole heart assessment to identify, characterize, and quantify plaque buildup.
New commercial insurance coverage for Cleerly: Learn more. Cleerly’s AI-enabled CCTA solution provides comprehensive, accurate, and trackable insights to personalize heart attack prevention. In the prospective, multicenter CREDENCE trial, Cleerly ISCHEMIA demonstrated higher diagnostic accuracy and area under the curve compared to FFRCT and stress testing, as referenced to 868 invasive measurements by fractional flow reserve (FFR), the ‘gold standard’ for determining ischemia.2 In a post-hoc analysis of the PACIFIC study, Cleerly ISCHEMIA was compared to FFRCT, 15O-H2O PET and SPECT to predict invasive FFR≤0.8 as reference standard. On a per-patient basis Cleerly ISCHEMIA, FFRCT and PET performed similarly and outperformed SPECT in predicting ischemia.2 Cleerly ISCHEMIA, using multivariate analysis, was the only non-invasive ischemia test that was prognostic of future MACE events, FFRCT and SPECT were not.2
Contact for pricing
No
Not available
Pricing model: freemium
Enterprise plans typically include dedicated support, custom integrations, and volume discounts. Contact the vendor for a personalized quote.